NCT03308201View on ClinicalTrials.gov

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

March 1, 2023

Conditions
Breast Cancer
Interventions
DRUG

Hemay022+exemestane

"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane."

DRUG

Hemay022+letrozole

Part two: Hemay022 combination with letrozole.

DRUG

Hemay022+ fulvestrant

Part two: Hemay022 combination with fulvestrant.

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Tianjin Hemay Pharmaceutical Co., Ltd

INDUSTRY

NCT03308201 - Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer | Biotech Hunter | Biotech Hunter